Responding to a lawsuit by Eli Lilly and two other companies, a federal judge Monday blocked a major White House initiative on prescription drug costs, saying the Trump administration lacked the legal authority to require drugmakers to disclose their prices in TV ads.
Several diabetes and health care advocacy groups on Thursday announced a seven-figure fundraising campaign to help fund their fight against what they consider “skyrocketing” insulin prices.
In recent months, the drugmaker has won federal approval to sell a drug called Emgality for two conditions: migraine pain and cluster headaches.
The American Medical Association Opioid Task Force 2019 Progress Report shows Indiana's reduction in opioid prescriptions from 2013 to 2018 is two percentage points higher than the national average.
Some of the biggest pharmaceutical companies, including Indianapolis-based Eli Lilly and Co., sued the Trump administration to try and block a rule that would force them to put the price of their drugs in television advertisements.
“Our central focus as a company is always to make lives better. … It’s a value that is core to every single employee who works here. So if we can have programs that reinforce that we are a company that is focused on making lives better, then we are doing something that connects to our mission and reminds our employees what really matters to us as a company.”
The fast-acting insulin, which diabetics inject shortly before each meal, is used by about 700,000 Americans.
The Indiana lawsuit was filed Monday against eight members of Sackler family who own Connecticut-based drugmaker Purdue Pharma.
The Trump administration has finalized regulations that will require drug companies to disclose list prices of medications costing more than $35 for a month’s supply.
A pharmaceutical company founder accused of paying doctors millions in bribes to prescribe a highly addictive fentanyl spray was convicted Thursday in a case that exposed such marketing tactics as using a stripper-turned-sales-rep to give a physician a lap dance.
Caprice R. Bearden, the company’s former compliance officer, pleaded guilty in November to multiple criminal charges related to the sale of over-potent drugs. She later testified against her boss, who was convicted and awaits sentencing.
Indianapolis-based Eli Lilly and Co. was one of the first drug firms to begin sharing prices. Now, others are following suit.
Bristol-Myers Squibb Co. on Friday won a shareholder vote to approve its takeover of Celgene Corp., paving the way to close the largest pharmaceutical merger in history and create a cancer-drug giant.
Paul Elmer, former owner and CEO of Pharmakon Pharmaceuticals in Noblesville, was convicted in federal court of nine counts of adulterating drugs and one count of conspiracy. He was acquitted of an additional count of obstruction of justice.
Paul Elmer, who founded Pharmakon 16 years ago and shut it down three years ago, faces charges of adulterating compounded drugs, conspiracy and obstructing a U.S. FDA investigation.
The suit accuses the companies of raising insulin sticker prices by more than 150 percent over five years, forcing diabetics to forgo the drug, take less insulin than needed or use expired versions
For a startup that has raised an eye-popping $71 million in just three years, Outpost Medicine LLC likes to keep a low profile. The young company, which is developing drugs for urinary and gastrointestinal disorders, is headquartered in small, unmarked space at the Parkwood Crossing office complex on East 96th Street. It has issued only a […]
The Trump administration Thursday unveiled a plan to channel now-hidden prescription drug rebates directly to patients, saying it would bypass middlemen and lower prices for consumers.